Long term outcomes of a randomized controlled clinical trial comparing the efficacy of Cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.

Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study.

Proposed sub- compartmentalisation of high infratemporal fossa involvement in gingivobuccal cancers and its impact on clinical outcome and AJCC 8th edition. A narrative review.

Long term toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin-ineligible head and neck cancer patients.

Anaplastic Cancer: Our Experience.

Change in Pattern of Failure in Head and Neck Cancer.

Non-surgical Organ preservation in Laryngeal and Hypopharyngeal Cancers: An audit from the clinic.

Prognostic value of radiological extranodal extension (rENE) detected by computed tomography (CT) for predicting outcomes in locally advanced head and neck squamous cell cancer (LAHNSCC) patients treated with radical concurrent chemoradiotherapy (CCRT).

Real-world data of use of nivolumab in platinum refractory head and neck cancers.

Real world evidence for use of NACT in locally advanced external auditory canal cancer.

Real world data of neoadjuvant and adjuvant chemotherapy in head neck osteosarcoma: Experience from a tertiary care center in India.

Metronomic systemic PCm (paclitaxel, carboplatin + metronomic) neoadjuvant chemotherapy in head and neck cancer.

A retrospective analysis of patients administered neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin with oral metronomic chemotherapy (OMCT) in locally advanced borderline resectable/technically unresectable head and neck cancers.

Phase III randomized control study evaluating adjuvant metronomic chemotherapy in locally advanced head and neck cancers post-radical chemoradiation (MACE-CTRT).

1-s2.0-S1368837522001051-main

PO-1094 Long term outcomes of 630 consecutive patients of oropharyngeal cancer treated with radiotherapy.

Safety and efficacy of pembrolizumab with chemotherapy in locally advanced head and neck cancers.

Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer—A case report.

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3- weeks cisplatin.

Prognostic and predictive roles of cancer stem cell markers in head and neck squamous cell carcinoma patients receiving chemoradiotherapy with or without nimotuzumab.

Hypomagnesemia in patients with locally advanced head and neck cancer treated weekly cisplatin-incidence and impact on outcomes.

Post hoc analysis of the screening log of phase III investigator‑initiated randomized clinical trial comparing palliative oral metronomic versus intravenous chemotherapy in head‑and‑neck cancer.

Prospective Phase II Open-Label Randomized Controlled Trial to Compare Mandibular Preservation in Upfront Surgery With Neoadjuvant Chemotherapy Followed by Surgery in Operable Oral Cavity Cancer.

Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral squamous cell carcinoma (OSCC).

Diclofenac versus tramadol for mucositis related pain in head and neck cancer patients undergoing concurrent chemoradiation – a phase 3 study

Concurrent chemoradiotherapy for locally advanced unresectable adenoid cystic carcinoma of head and neck: experience from a single institute.

Audit of Demographics, Treatment Patterns and Outcomes of Differentiated Thyroid Cancers Treated with Tyrosine Kinase Inhibitors.

Weight loss and its impact on outcome in head and cancer patients during chemo-radiation.

Delirium and seizures in a patient with head-and-neck squamous cell carcinoma on docetaxel, cisplatin, and 5-fluorouracil.

The efficacy of low-dose immunotherapy in head-and-neck cancer

Quality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel in recurrent head and neck cancer

Adding to the debate on once-a-week versus once-every-3-weeks cisplatin dosing in concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer

Quality of life and quality-adjusted time without toxicity in palliatively treated head-and-neck cancer patients

Distress Management in Patients With Head and Neck Cancer Before Start of Palliative Chemotherapy: A Practical Approach

Long-term survival outcomes of technically unresectable carcinoma maxilla postinduction chemotherapy

Influence of Hypothyroidism After Chemoradiation on Outcomes in Head and Neck Cancer

Toxicity and tolerance of concurrent docetaxel with radiotherapy in cisplatin ineligible head and neck cancer patients.

Results of a randomized phase III study of nimotuzumab in combination with concurrent radiotherapy and cisplatin versus radiotherapy and cisplatin alone, in locally advanced squamous cell carcinoma of the head and neck.

Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.

Aspiration pneumonia in head and neck cancer patients undergoing concurrent chemoradiation from India: Findings from a post hoc analysis of a phase 3 study.

910P Repurposing pantoprazole in advanced head and neck squamous cell carcinoma: A phase I/II randomized study.

865MO RMAC study: A randomized study evaluating the efficacy of metronomic adjuvant chemotherapy in patients with recurrent head and neck cancers post salvage surgery, not eligible for re-irradiation.

An Audit of Systemic Therapy in Medullary Carcinoma Thyroid.

Systemic Therapy in Thyroid Cancer.

Advances in pharmacotherapy for head and neck cancer.

Post hoc analysis of a randomized controlled trial comparing concurrent chemoradiation with cisplatin versus nimotuzumab-cisplatin, focusing on acute oral mucositis.

Outcome of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).

Aprepitant for patients with head-and-neck cancer receiving once-a-week cisplatin with radiation: Is it required?.

Correlation of transcriptionally active human papillomavirus status with the clinical and molecular profiles of head and neck squamous cell carcinomas.

Intensity‐modulated radiation therapy for nasal cavity and paranasal sinus tumors: Experience from a single institute.

The Pattern of Care of Use of Nivolumab in Head and Neck Cancers – Audit From a Tertiary Cancer Centre.

Oral metronomic therapy in head and neck cancer – Authors' reply.

FGFR alterations in head-and-neck cancer.

SAFETY AND EFFICACY OF CONCURRENT CHEMORADIOTHERAPY FOR HEAD-AND-NECK CANCERS IN OLDER VERSUS YOUNGER PATIENTS: POST HOC ANALYSIS OF A RANDOMISED CONTROLLED TRIAL.

Chemoradiation in Unresectable Oral Cavity Cancer: A Myth or Reality!.

Safety and efficacy of concurrent chemoradiotherapy for head-and-neck cancers in older versus younger patients: Post hoc analysis of a randomized controlled trial.

Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.

Molecular tumor board: Case 4 Salivary Gland Cancer: Novel therapeutic options as a result of comprehensive molecular profiling.

Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial.

Articles Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel- group, non-inferiority, randomised, phase 3 trial.

Long‑term outcomes of locally advanced and borderline resectable esthesioneuroblastoma and sinonasal tumor with neuroendocrine differentiation treated with neoadjuvant chemotherapy.

Beyond conventional chemotherapy, targeted therapy and immunotherapy in squamous cell cancer of the oral cavity.

Incidence and Outcome of Second Malignancy in Primary Treated Head and Neck Cancer.

Salvage surgery in head and neck cancer: Does it improve outcomes?.

Indication of adjuvant chemoradiation post neoadjuvant chemotherapy in very locally advanced borderline resectable head and neck cancer.

Optimal cumulative cisplatin dose for radio-sensitization in locally advanced head and neck cancer.

Hypothyroidism and its impact on outcomes in head and neck cancer.

A phase III randomized clinical trial of diclofenac versus tramadol for mucositis-related pain in head and neck cancer patients undergoing concurrent chemoradiation.

Incidence of 5-fluorouracil related in cardiotoxicity in patients with head and neck cancer.

Second malignancy post-chemoradiation in head and neck cancer patients.

Results of a phase II randomized controlled clinical trial comparing efficacy of Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.

Evolving role of immunotherapy in head-and-neck cancers: A systemic review.

Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.

Current and Emerging Role of Chemotherapy in Oral Cancer.

Retrospective analysis of palliative metronomic chemotherapy in head and neck cancer.

343PQTWiST analysis to compare the benefit of Metronomic chemotherapy versus intravenous cisplatin for patients with Head and neck cancer.

337OQuality of life without toxicity or symptoms analysis of a randomized controlled clinical trial comparing efficacy of Cabazitaxel versus docetaxel in recurrent Head and Neck Cancer.

342PQOL analysis of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second line or above therapy in recurrent head and neck cancer.

Results of a phase II randomized controlled clinical trial comparing efficacyof Cabazitaxel versus Docetaxel as second line or above therapy in recurrent head and neck cancer.

1098PIncidence and impact of DPD mutation on neoadjuvant chemotherapy in head and neck cancers.

Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer.

Results of a phase II randomized controlled clinical trial comparing efficacy of cabazitaxel versus docetaxel as second-line or above therapy in recurrent head and neck cancer.

Incidence and impact of Dihydropyrimidine dehydrogenase gene mutation on neoadjuvant chemotherapy in head and neck cancers.

Carboplatin-based concurrent chemoradiation therapy in locally advanced head and neck cancer patients who are unfit for cisplatin therapy.

Neoadjuvant chemotherapy in geriatric head and neck cancers.

Role of neoadjuvant chemotherapy in advanced carcinoma of the hypopharynx and larynxLetter to the Editor.

A tertiary care experience with paclitaxel and cetuximab as palliative chemotherapy in platinum sensitive and nonsensitive in head and neck cancers.

Expectations and preferences for palliative chemotherapy in head and neck cancers patients.

386P Expectations and preferences for palliative chemotherapy in head and neck cancers patients.

Toxicity analysis of docetaxel, cisplatin, and 5-fluorouracil neoadjuvant chemotherapy in Indian patients with head and neck cancers.

Dihydropyrimidine dehydrogenase mutation in neoadjuvant chemotherapy in head and neck cancers: Myth or reality?.

Preoperative Chemotherapy and Metronomic Scheduling of Chemotherapy in Locally Advanced Oral Cancers.

Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.

Toxicity, tolerance and outcomes of carboplatin based CTRT ( concurrent chemoradiation) in head and neck cancers in patients who were not fit for cisplatin based CTRT.

Time-Dependent Area under the ROC Curve for Optimum Biological Dose Detection.

An audit of the results of a triplet metronomic chemotherapy regimen incorporating a tyrosine kinase inhibitor in recurrent/metastatic head and neck cancers patients.

Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India.

Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India.

Metronomic palliative chemotherapy in maxillary sinus tumor.

Efficacy of second‑line erlotinib in patients postprogression of first‑line chemotherapy in head and neck cancers.

Technically unresectable recurrent oral cancers: Is NACT the answer?.

Head and neck cancer in geriatric patients: Analysis of the pattern of care given at a tertiary cancer care center.

Cisplatin based adjuvant chemoradiation following neoadjuvant chemotherapy and surgery in advanced oral cavity cancers: A deliverable regimen?.

Molecular biology of head and neck cancers.

Chemoprevention in head and neck cancer.

Extra-lymphatic filariasis at reconstructive surgery flap site recurrence of head and neck cancer.

Neoadjuvant chemotherapy and surgical margin in technically unresectable buccal mucosa cancers.

Compliance With Neoadjuvant Chemotherapy in T4 Oral Cancers: Place, Person, Socioeconomic Status, or Assistance.

Neoadjuvant chemotherapy in advanced sinonasal teratocarcinosarcoma with intracranial extension: Report of two cases with literature review.

Does the use of induction chemotherapy in oral cavity cancer compromise subsequent loco-regional treatment delivery: Results from a matched pair analysis.

Neoadjuvant Chemotherapy in Technically Unresectable Oral Cancers: Does Human Papillomavirus Make a Difference?.

Neoadjuvant chemotherapy in technically unresectable carcinoma of external auditory canal.

Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers.

NACT in locally advanced oral cancers : Does HPV make a difference?.

Compliance to NACT in T4 oral cancers :The place, person, socioeconomic status or assistance.

Effect of early integration of specialized palliative care into standard oncologic treatment on the quality of life of patients with advanced head and neck cancers: A phase III randomized controlled trial.

Quality of life in patients with locally advanced head and neck cancer undergoing chemoradiation with once-a-week versus once-every-three-weeks cisplatin.

Low-cost oral metronomic versus intravenous chemotherapy in recurrent, inoperable and metastatic head and neck cancer: Phase III Metro-CIS study.

Prognostic value of radiological extranodal extension detected by computed tomography for predicting outcomes in head and neck squamous cell cancer patients treated with radical chemoradiotherapy.

A prospective phase II open-label randomized controlled trial to compare mandibular preservation in upfront surgery to neoadjuvant chemotherapy followed by surgery in operable oral cavity cancer.

Aprepitant in weekly cisplatin with radiation in head and neck cancer: Is it required?.

Efficacy and safety of neoadjuvant chemotherapy (NACT) with paclitaxel plus carboplatin and oral metronomic chemotherapy (OMCT) in patients with technically unresectable oral cavity squamous cell carcinoma (SCC).

Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic.

Clinical outcomes for nasopharyngeal cancer with intracranial extension after taxane-based induction chemotherapy and concurrent chemo-radiotherapy in the modern era.

Indian clinical practice guideline for the management of hypopharyngeal carcinoma: A consensus statement.

Indian clinical practice guideline for the management of nasopharyngeal carcinoma: A consensus statement.

Indian clinical practice guideline for the management of squamous cell carcinoma of head and neck: A consensus statement.

Indian clinical practice guideline for the management of oral cavity cancer: A consensus statement.

Indian clinical practice guideline for the management of oropharyngeal carcinoma: A consensus statement.

Indian clinical practice guideline for the management of laryngeal carcinoma: A consensus statement.

Nimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV negative oropharyngeal cancer.

Palliative chemotherapy in head and neck cancer: balancing between beneficial and adverse effects.

The pattern of care in head-and-neck cancer: Comparison between before and during the COVID-19 pandemic.

Effect of Early Palliative Care on the Quality of Life of Patients with Advanced Head and Neck Cancers: A Phase 3 Randomized Controlled Trial.

Palliative oral triple metronomic chemotherapy in a patient with head-and-neck cancer during the COVID-19 pandemic in India: A case report.

Patterns of failure and outcomes in cT4 Oral squamous cell carcinoma (OSCC) undergoing upfront surgery in comparison to Neo-Adjuvant Chemotherapy (NACT) followed by surgery: A Matched Pair analysis.

DOES AGE MATTER FOR RADICAL CHEMORADIATION IN HEAD AND NECK CANCER: A POST-HOC ANALYSIS OF A RANDOMIZED STUDY.

288OMolecular profiling and treatment patterns of advanced salivary gland cancers in head and neck region.

1121PNimotuzumab-cisplatin-radiation versus cisplatin-radiation in HPV-negative oropharyngeal cancer.

Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/ Early-Failure Oral Cancer.

A Randomized Phase 3 Trial Comparing Nimotuzumab Plus Cisplatin Chemoradiotherapy Versus Cisplatin Chemoradiotherapy Alone in Locally Advanced Head and Neck Cancer.

Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort.

NUT Midline Carcinoma.

Nimotuzumab Dosing and Outcomes in Locally Advanced Head and Neck Cancer.

Palliative chemotherapy in carcinoma nasopharynx.

A-prospective-randomized-phase-II-study-comparing-metronomic-chemotherapy-with-chemotherapy-single-agent-cisplatin-in-patients-with-metastatic-relapse.

Excellent response to oral Metronomic chemotherapy in unresectable adenocarcinoma of external auditory canal.

Does DeCIDE Give a Decisive Answer Against Induction Chemotherapy in Head and Neck Cancers?.

Locoregional recurrences after postoperative Volumetric Modulated Arc Radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting : experience and lessons learned.

A prospective randomized phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck.

Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?.

Neoadjuvant chemotherapy followed by surgery in very locally advanced technically unresectable oral cavity cancers.

How safe is adjuvant RapidArc in Oral Cavity Cancers: An analysis of Marginal and Outfield Failures.

Recurrent sinonasal teratocarcinosarcoma with intracranial extension: Case report.

Weekly chemotherapy as Induction chemotherapy in locally advanced head and neck cancer for patients ineligible for 3 weekly maximum tolerable dose chemotherapy.

Tolerance and toxicity of neoadjuvant docetaxel, cisplatin and 5 fluorouracil regimen in technically unresectable oral cancer in resource limited rural based tertiary cancer center.

A phase II study comparing metronomic chemotherapy with chemotherapy (single-agent cisplatin), in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of head and neck.

Neoadjuvant chemotherapy in very locally advanced technically unresectable oral cavity cancers.

Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus.

PCN157. Health Related Quality of Life in Patients with Metastatic, Relapsed, or Inoperable Squamous Cell Carcinoma of the Head and Neck in India.

Guidelines for treatment of recurrent or metastatic head and neck cancer.

Referral pattern for neoadjuvant chemotherapy in the head and neck cancers in a tertiary care center.

Is there a role of induction chemotherapy followed by resection in T4b oral cavity cancers?.

Comparison of concomitant boost radiotherapy against concurrent chemoradiation in locally advanced oropharyngeal cancers: A phase III randomised trial.

Induction chemotherapy in technically unresectable locally advanced oral cavity cancers: Does it make a difference?.

Neo-adjuvant chemotherapy in advanced hypopharyngeal carcinoma.

Epidemiology of oral cancers referred for NACT, the demographics, clinical profile, and organ functions.

Are three drugs better than two and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?.

Acute toxicity of neoadjuvant chemotherapy in oral cavity cancers: Can it be predicted?.

OP048: Induction chemotherapy in unresectable oral cavity cancers.

Oral Metronomic Chemotherapy in Recurrent, Metastatic and Locally Advanced Head and Neck Cancers.

Is There a Limitation of RECIST Criteria in Prediction of Pathological Response, in Head and Neck Cancers, to Postinduction Chemotherapy?.

Development of hyponatremia on neoadjuvant chemotherapy in locally advanced head & neck cancers.

Neoadjuvant chemotherapy followed by definitive local treatment in locally advanced carcinoma maxillary sinus.

Palliative chemotherapy in head and neck cancers: A tertiary care center experience with weekly paclitaxel and cetuximab.

Metronomic chemotherapy in advanced oral cancers.

Conformal Radiotherapy in the Treatment of Advanced Juvenile Nasopharyngeal Angiofibroma With Intracranial Extension: An Institutional Experience.

Acute Toxicities Experienced during Simultaneous Integrated Boost Intensity-modulated Radiotherapy in Head and Neck Cancers - Experience from a North Indian Regional Cancer Centre.

Preliminary results of SIB-IMRT in head and neck cancers: Report from a regional cancer center in northern India.

QOL assessment in head and neck cancer patients undergoing neoadjuvant chemotherapy and its impact on overall survival.

A phase II randomized control trial of erlotinib in combination with celecoxib in patients with operable oral squamous cell carcinoma (OSCC): Erlo-Xib Study.

Dermatofibrosarcoma protuberans of head and neck: Clinical outcome of nine cases treated with imatinib.